Survival After Abdominal Q-M Type B versus C2 Radical Hysterectomy for Early-Stage Cervical Cancer

Abstract

Chunlin Chen,1,* Wuliang Wang,2,* Ping Liu,1,* Pengfei Li,1,* Lu Wang,1 Shuangling Jin,3 Xiaonong Bin,4 Jinghe Lang1,5 1Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People’s Republic of China; 2Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, People’s Republic of China; 3Department of Obstetrics and Gynecology, Peace Hospital Affiliated to Changzhi Medical College, Changzhi 046000, People’s Republic of China; 4Department of Epidemiology, College of Public Health, Guangzhou Medical University, Guangzhou 511436, People’s Republic of China; 5Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chunlin Chen; Jinghe LangDepartment of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue, Guangzhou 510515, People’s Republic of ChinaTel/Fax [phone]Email [email protected]; [email protected]: To evaluate the survival outcomes of abdominal Q-M type B and type C2 radical hysterectomy (RH) for early-stage (IA1 (lymphovascular invasion)-IIA2) cervical cancer.Patients and methods: Based on this multicenter, retrospective cohort study on the clinical diagnosis and treatment for cervical cancer in China (Four C), the survival outcomes of abdominal type B and type C2 RH for early-stage cervical cancer were compared under real-world and matched cohort study conditions.Results: In total, 46,313 cases were included in the Four C database, among whom 20,018 underwent abdominal type B or type C2 RH. In the real-world study, no differences were found in the 5-year overall survival (OS) between the type B group (n=15,471) and type C2 group (n=4547), but the 5-year disease-free survival (DFS) was lower in the type C2 group (82.1 vs 84.8%, hazard ratio: 1.144). Based on the inclusion criteria, 9135 cases were included and the type C2 group (n=1818) was found to have a lower 5-year OS and DFS (OS: 89.5 vs 92.0%, hazard ratio: 1.393; DFS: 84.3 vs 87.4%, hazard ratio: 1.342). Subsequently, 1799 cases from each group were matched and the type C2 group had a lower 5-year DFS (84.6 vs 88.4%, hazard ratio: 1.332). Upon further analysis of the subgroups, the type C2 group had a lower 5-year OS and DFS (OS: 90.3 vs 93.8%, hazard ratio: 1.522; DFS: 85.2 vs 89.4%, hazard ratio: 1.439).Conclusion: Q-M type B RH could be used for the treatment of stage IA1 (lymphovascular invasion)-IIA2 cervical cancer.Keywords: cervical cancer, early-stage, Q-M type B, survival outcome

Keywords

• cervical cancer
• early-stage
• q-m type b
• survival outcome